GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Cyclically Adjusted Book per Share

Zealand Pharma A/S (Zealand Pharma A/S) Cyclically Adjusted Book per Share : $3.55 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zealand Pharma A/S's adjusted book value per share for the three months ended in Mar. 2024 was $6.644. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Zealand Pharma A/S's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Zealand Pharma A/S was 6.90% per year. The lowest was 4.40% per year. And the median was 5.65% per year.

As of today (2024-05-17), Zealand Pharma A/S's current stock price is $87.55. Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.55. Zealand Pharma A/S's Cyclically Adjusted PB Ratio of today is 24.66.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma A/S was 31.77. The lowest was 3.30. And the median was 9.75.


Zealand Pharma A/S Cyclically Adjusted Book per Share Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted Book per Share Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.75 3.32 3.33 3.14 3.46

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.65 3.18 3.27 3.46 3.55

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.644/118.4000*118.4000
=6.644

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.411 99.700 2.863
201409 2.419 99.700 2.873
201412 1.851 99.400 2.205
201503 1.341 100.200 1.585
201506 1.069 100.300 1.262
201509 1.022 100.200 1.208
201512 1.547 99.800 1.835
201603 1.119 100.200 1.322
201606 0.677 100.600 0.797
201609 1.286 100.200 1.520
201612 1.542 100.300 1.820
201703 1.420 101.200 1.661
201706 1.070 101.200 1.252
201709 3.334 101.800 3.878
201712 2.667 101.300 3.117
201803 2.358 101.700 2.745
201806 1.616 102.300 1.870
201809 6.322 102.400 7.310
201812 5.541 102.100 6.426
201903 5.195 102.900 5.978
201906 4.605 102.900 5.299
201909 5.807 102.900 6.682
201912 4.934 102.900 5.677
202003 4.871 103.300 5.583
202006 6.841 103.200 7.849
202009 6.340 103.500 7.253
202012 5.051 103.400 5.784
202103 6.165 104.300 6.998
202106 5.160 105.000 5.819
202109 4.346 105.800 4.864
202112 3.262 106.600 3.623
202203 2.432 109.900 2.620
202206 1.555 113.600 1.621
202209 1.053 116.400 1.071
202212 2.257 115.900 2.306
202303 1.870 117.300 1.888
202306 4.315 116.400 4.389
202309 4.460 117.400 4.498
202312 3.992 116.700 4.050
202403 6.644 118.400 6.644

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Zealand Pharma A/S  (OTCPK:ZLDPF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zealand Pharma A/S's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=87.55/3.55
=24.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma A/S was 31.77. The lowest was 3.30. And the median was 9.75.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zealand Pharma A/S Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines

From GuruFocus

Zealand Pharma completes registration of capital increase

By PurpleRose PurpleRose 07-13-2022